Evidence map›Paper›PMID 24847086›Full record

ArticleNeuro-oncology2014

The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010.

Quinn T Ostrom, Yanwen Chen, Peter M de Blank, Annie Ondracek, Paul Farah, Haley Gittleman, Yingli Wolinsky, Carol Kruchko, Mark L Cohen, Daniel J Brat and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 4 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 4 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. A case-control study of MRI features in pediatric atypical teratoid rhabdoid tumor and medulloblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Quinn T OstromCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Yanwen ChenCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Peter M de BlankCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Annie OndracekCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Paul FarahCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Haley GittlemanCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Yingli WolinskyCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Carol KruchkoCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Mark L CohenCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Daniel J BratCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Jill S Barnholtz-SloanCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Central Brain Tumor Registry of the United States · USCase Western Reserve University · USUniversity School · USEmory University Hospital · USThe Ohio State University · USUniversity Hospitals Case Medical Center · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
INTEGRATION OF BEST PRACTICES FOR COLLECTION AND REPORTING OF PRIMARY MALIGNANT AU58DP003831 · DP · CENTRAL BRAIN TUMOR REGISTRY OF THE U S · PI KRUCHKO, CAROL · 2011 to 2014
$499k
NCCDPHP CDC HHS 5U58DP003831NCI NIH HHS P30 CA043703
6 · The paper itself

Abstract

backgroundAtypical teratoid/rhabdoid tumor is a rare malignant CNS tumor that most often affects children ≤ 3 years old. The Central Brain Tumor Registry of the United States contains the largest aggregation of population-based incidence data for primary CNS tumors in the US. Its data were used to describe the incidence, associated trends, and relative survival after diagnosis of atypical teratoid/rhabdoid tumor.

methodsUsing data from 50 cancer registries between 2001 and 2010, age-adjusted incidence rates per 100 000 and 95% CIs were calculated by sex, race, Hispanic ethnicity, age at diagnosis, and location of tumor in the CNS for children aged 0 to 19 years. Relative survival rates and 95% CIs were also calculated.

resultsThe average annual age-adjusted incidence rate was 0.07 (95% CI: 0.07, 0.08). Incidence rates did not significantly vary by sex, race, or ethnicity. Age had a strong effect on incidence rate, with highest incidence among children <1 year, and decreasing incidence with increasing age. The 6-month, 1-year, and 5-year relative survival rates for all ages were 65.0%, 46.8%, and 28.3%, respectively. Atypical teratoid/rhabdoid tumor can occur anywhere in the CNS, but supratentorial tumors were more common with increasing age.

conclusionWe confirm differences in survival by age at diagnosis, treatment pattern, and location of tumor in the brain. This contributes to our understanding of these tumors and may stimulate research leading to improved treatment of this devastating childhood disease.

Indexed as

AdolescentAdultAge FactorsBrain NeoplasmsChildChild, PreschoolFemaleHumansIncidenceInfantInfant, NewbornMaleRegistriesRhabdoid TumorSurvival AnalysisTeratomaatypical teratoid/rhabdoid tumorsbrain tumorsincidencepediatric brain tumorssurvival

Identifiers

PMID24847086
PMCPMC4165422
OpenAlexW2098118986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.